Follow the SynAct Pharma AB stock price and the full directors' dealings record of the company, a publicly traded company based in Finland. Shares are quoted on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, SynAct Pharma AB has logged 11 insider filings. Market capitalisation: €974.4m. The latest transaction was reported on 7 September 2026 (Sale). Among the most active insiders: Thomas Jonassen. All data is openly available.
11
Insider Decl.
n/a
Thresholds
€26,965
4 ops.
Buy Volume
€872,452
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate SynAct Pharma AB Strong Buy (bullish), based on 2 analysts. Average price target: SEK 35.00.
35Σ signal
Buys €26,965€872,452 Sells
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
SynAct Pharma AB es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades inflamatorias y autoinmunes. Cotiza en la Bolsa de Estocolmo (XSTO).